Cenicriviroc, an orally active CCR5 antagonist for the potential treatment of HIV infection

Current Opinion in Investigational Drugs

Volumn 11, Issue 8, 2010, Pages 940-950

  Klibanov, Olga M ^a   Williams, Shannon H ^a   Iler, Cameron A ^a  

^a WINGATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

8 [4 (2 BUTOXYETHOXY)PHENYL] 1,2,3,4 TETRAHYDRO 1 ISOBUTYL N [4 (1 PROPYL 1H IMIDAZOL 5 YLMETHYLSULFINYL)PHENYL] 1 BENZAZOCINE 5 CARBOXAMIDE; 8 [4 [2 (BUTOXY)ETHOXY] PHENYL] 1 ISOBUTYL N [4 [[(1 PROPYL 1H IMIDAZOL 5 YL) METHYL]SULFINYL]PHENYL] 1,2,3,4 TETRAHYDRO 1 BENZAZOCINE 5 CARBOXAMIDE METHANESULFONATE; ANCRIVIROC; APLAVIROC; ATAZANAVIR; CENICRIVIROC; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; DARUNAVIR; EFAVIRENZ; ENFUVIRTIDE; ETRAVIRINE; INDINAVIR; IODINE 125; LAMIVUDINE; LOPINAVIR; MARAVIROC; N [4 [[[6,7 DIHYDRO 2 (4 METHYLPHENYL) 5H BENZOCYCLOHEPTEN 8 YL]CARBONYL]AMINO]BENZYL] N,N DIMETHYL 2H TETRAHYDROPYRAN 4 AMINIUM CHLORIDE; RALTEGRAVIR; TBR 220; TBR 652; TOBIRA; UNCLASSIFIED DRUG; VICRIVIROC; ZIDOVUDINE;

ABDOMINAL PAIN; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIINFLAMMATORY ACTIVITY; ANTIVIRAL ACTIVITY; AREA UNDER THE CURVE; ARTHRALGIA; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BACKACHE; BLOOD PRESSURE; BLURRED VISION; CLINICAL TRIAL; CONSTIPATION; CONTACT DERMATITIS; DIARRHEA; DIZZINESS; DRUG ABSORPTION; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG METABOLISM; DRUG POTENCY; DRUG POTENTIATION; DRUG STRUCTURE; DRUG SYNTHESIS; DYSPEPSIA; ECG ABNORMALITY; FATIGUE; GASTROINTESTINAL REFLUX; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPESTHESIA; IN VITRO STUDY; INFLAMMATORY DISEASE; INSOMNIA; LACTATE DEHYDROGENASE BLOOD LEVEL; MACROPHAGE; NAUSEA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; QT PROLONGATION; REVIEW; RHEUMATOID ARTHRITIS; RHINOPHARYNGITIS; SIDE EFFECT; SINGLE DRUG DOSE; SINUSITIS; STRUCTURE ACTIVITY RELATION; T LYMPHOCYTE; TROPICS; VIRUS INHIBITION; VIRUS REPLICATION; VIRUS RESISTANCE; VITAL SIGN;

ADMINISTRATION, ORAL; ANTI-HIV AGENTS; CLINICAL TRIALS AS TOPIC; CLINICAL TRIALS, PHASE I AS TOPIC; DRUG COMBINATIONS; DRUG RESISTANCE, VIRAL; HIV INFECTIONS; HIV-1; HUMANS; IMIDAZOLES; RECEPTORS, CCR5;

EID: 77954971781     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (52)

1. 307172 Identification of RANTES, MIP-1α and MIP-1? as the major HIV-suppressive factors produced by CD8+ T cells. Cocchi F, DeVico AL, Garzino-Demo A, Arya SK, Gallo RC, Lusso P SCIENCE 1995 270 1811-1815
2. 386260 Chemokine receptors as HIV-1 coreceptors: Roles in viral entry, tropism and disease. Berger EA, Murphy PM, Farber JM ANNU REV IMMUNOL 1999 17 657-700
3. 569298 A binding pocket for a small-molecule inhibitor of HIV-1 entry within the transmembrane helices of CCR5. Dragic T, Trkola A, Thompson DAD, Cormier EG, Kajumo FA, Maxwell E, Lin SW, Ying W, Smith SO, Sakmar TP, Moore JP PROC NATL ACAD SCI USA 2000 97 10 5639-5644
4. 569301 Discovery of novel, potent, and selective small-molecule CCR5 antagonists as anti-HIV-1 agents: Synthesis and biological evaluation of anilide derivatives with a quaternary ammonium moiety. Shiraishi M, Aramaki Y, Seto M, Imoto H, Nishikawa Y, Kanzaki N, Okamoto M, Sawada H, Nishimura O, Baba M, Fujino M J Med Chem 2000 43 10 2049-2063
5. 576665 Analysis of the mechanism by which the small-molecule CCR5 antagonists SCH-351125 and SCH-350581 inhibit human immunodeficiency virus type 1 entry. Tsamis F, Gavrilov S, Kajumo F, Seibert C, Kuhmann S, Ketas T, Trkola A, Palani A, Clader JW, Tagat JR, McCombie S et al J Virol 2003 77 9 5201-5208
6. 589413 Discovery of a highly potent and orally active CCR5 antagonist TAK-652 as an anti-HIV-1 agent: Synthesis and biological activities of 1-benzazocine derivatives containing sulfoxide moiety. Seto M, Aikawa K, Aramaki Y, Miyamoto N, Kanzaki N, Kuze Y, Takashima K, Baba M, Shiraishi M ACS 2005 229 San Diego MEDI 89
7. 589878 TAK-652, a novel small molecule CCR5 antagonist with potent anti-HIV-1 activity. Baba M, Kanzaki N, Miyake H, Wang X, Takashima K, Teshima K, Shiraishi M, and Iizawa Y INT CONF RETROVIRUSES OPPORTUNISTIC INFECT 2005 12 Boston Abs 541
8. 676363 Highly potent and orally active CCR5 antagonists as anti-HIV-1 agents: Synthesis and biological activities of 1-benzazocine derivatives containing a sulfoxide moiety. Seto M, Aikawa K, Miyamoto N, Aramaki Y, Kanzaki N, Takashima K, Kuze Y, Iizawa Y, Baba M, Shiraishi M J MED CHEM 2006 49 6 2037-2048
9. 772178 Isolation and characterization of human immunodeficiency virus type 1 resistant to the small-molecule CCR5 antagonist TAK-652. Baba M, Miyake H, Wang X, Okamoto M, Takashima K ANTIMICROB AGENTS CHEMOTHER 2007 51 2 707-715
10. 774305 Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitor-bound receptor for entry. Westby M, Smith-Burchnell C, Mori J, Lewis M, Mosley M, Stockdale M, Dorr P, Ciaramella G, Perros M J Virol 2007 81 5 2359-2371
11. 802326 The CCR5 and CXCR4 coreceptors-central to understanding the transmission and pathogenesis of human immunodeficiency virus type 1 infection. Moore JP, Kitchen SG, Pugach P, Zack JA AIDS RES HUM RETROVIRUSES 2004 20 1 111-126
12. 818256 Takeda to license CCR5 antagonists for treatment of HIV infection to Tobira Therapeutics, Inc. Takeda Pharmaceutical Co Ltd PRESS RELEASE 2007 August 01
13. 884619 Hepatotoxicity observed in clinical trials of aplaviroc (GW873140). Nichols WG, Steel HM, Bonny T, Adkison K, Curtis L, Millard J, Kabeya K, Clumeck N ANTIMICROB AGENTS CHEMOTHER 2008 52 3 858-865
14. 896841 Schering-Plough initiates phase II study with vicriviroc in treatment-naive HIV-infected patients. Schering-Plough Corp PRESS RELEASE 2008 April 15
15. 901163 Incyte reports first quarter financial results and positive clinical progress in multiple programs. Incyte Corp PRESS RELEASE 2008 April 30
16. 936243 Tobira Therapeutics Inc: Pipeline. Tobira Therapeutics Inc COMPANY WORLD WIDE WEB SITE 2008 August 19
17. 969323 HIV/AIDS surveillance report: Cases of HIV infection and AIDS in the United States and dependent areas, 2005. Centers for Disease Controls and Prevention COMPANY PUBLICATION 2007 Volume17, Revised Edition June 28
18. 974174 Molecular interactions of CCR5 with major classes of small-molecule anti-HIV CCR5 antagonists. Kondru R, Zhang J, Ji C, Mirzadegan T, Rotstein D, Sankuratri S, Dioszegi M MOL PHARMACOL 2008 73 3 789-800
19. 999257 Tobira Therapeutics Inc. initiates proof of concept study with TAK-652 for the treatment of HIV. Tobira Therapeutics Inc PRESS RELEASE 2009 April 09
20. 1007325 Treatment for adult HIV infection: 2006 Recommendations of the International AIDS Society-USA panel. Hammer SM, Saag MS, Schechter M, Montaner JS, Schooley RT, Jacobsen DM, Thompson MA, Carpenter CC, Fischl MA, Gazzard BG, Gatell JM et al JAMA-J AM MED ASSOC 2006 296 7 827-843
21. 1007332 The prevalence of antiretroviral drug resistance in the United States. Richman DD, Morton SC, Wrin T, Hellmann N, Berry S, Shapiro MF, Bozzette SA AIDS 2004 18 10 1393-1401
22. 1007341 Long-term probability of detection of HIV-1 drug resistance after starting antiretroviral therapy in routine clinical practice. Phillips AN, Dunn D, Sabin C, Pozniak A, Matthias R, Geretti AM, Clarke J, Churchill D, Williams I, Hill T, Green H et al AIDS 2005 19 5 487-494
23. 1007357 Targeting chemokine receptors in HIV: A status report. Kuhmann SE, Hartley O ANNU REV PHARMACOL TOXICOL 2008 48 425-461
24. 1007575 The crown and stem of the V3 loop play distinct roles in human immunodeficiency virus type 1 envelope glycoprotein interactions with the CCR5 coreceptor. Cormier EG, Dragic T J VIROL 2002 76 8953-8957
25. 1007600 An overview of the determinants of CCR5 and CXCR4 co-receptor function. Dragic T J GEN VIROL 2001 82 8 1807-1814
26. 1035877 In vitro anti-HIV efficacy of the chemokine receptor 5 (CCR5) antagonist TBR-652 in combination with four other classes of antiretroviral agents. Palleja S, Ogden R, Hamy F, Vidal V, Klimkait T, Martin D, Driz R, Sapirstein J ICAAC 2009 49 September 13 Abs H-933
27. 1036244 TBR-652, a chemokine receptor 5 (CCR5) antagonist, demonstrates good oral bioavailability and desirable pharmacokinetic (PK) and safety profiles in healthy volunteers. Palleja S, Wang-Smith L, Ogden R, Martin D, Driz R, Sapirstein J ICAAC 2009 49 September 14 Abs A1-1308
28. 1040401 Tobira Therapeutics company website. Tobira Therapeutics Inc COMPANY WORLD WIDE WEB SITE 2009 September 09
29. 1064526 Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents - A Working Group of the Office of AIDS Research Advisory Council (OARAC) Internet site 2009 December 01
30. 1092257 TAK-652, a novel CCR5 inhibitor, has favourable drug interactions with other antiretrovirals in vitro. Tremblay CL, Giguel F, Chou TC, Dong HJ, Takashimo K, Hirsch MS ANTIVIR THER 2005 10 8 967-968
31. 1092259 TAK-652 inhibits CCR5-mediated human immunodeficiency virus type 1 in vitro and has favorable pharmacokinetics in humans. Baba M, Takashima K, Miyake H, Kanzaki N, Teshima K, Wang X, Shiraishi M, Iizawa Y ANTIMICROB AGENTS CHEMOTHER 2005 49 11 4584-4591
32. 1092262 The relative activity of "function sparing" HIV-1 entry inhibitors on viral entry and CCR5 internalization: Is allosteric functional selectivity a valuable therapeutic property? Muniz-Medina VM, Jones S, Maglich JM, Galardi C, Hollingsworth RE, Kazmierski WM, Ferris RG, Edelstein MP, Chiswell KE, Kenakin TP MOL PHARMACOL 2009 75 3 490-501
33. 1092266 Pharmacokinetics and pharmacodynamics of TBR 652, a chemokine receptor 5 antagonist, in HIV-1-infected, ART-experienced, CCR5 antagonist-naive patients. Martin D, Palleja S, Pheng L, Trinh MM, Marier J-F, Sapirstein J INT CONF RETROVIRUSES OPPORTUNISTIC INFECT 2010 17 Abs 598
34. 1092269 Safety and efficacy of TBR652, a CCR5 antagonist, in HIV-1-infected, ART-experienced, CCR5 antagonist-nave patients. Palleja S, Cohen C, Gathe J, Thompson M, DeJesus E, Brinson C, Elion R, Galindez J, Martin D, Sapirstein J INT CONF RETROVIRUSES OPPORTUNISTIC INFECT 2010 17 Abs 53
35. 1092275 TAK-652, a novel small molecule inhibitor of CCR5 has favorable anti-HIV interactions with other antiretrovirals in vitro. Tremblay CL, Giguel F, Chou TC, Dong H, Lizawa Y, Shiraishi M, Hirsch M INT CONF RETROVIRUSES OPPORTUNISTIC INFECT 2005 12 Abs 542
36. 1092291 TBR-652, a new chemokine receptor 5 (CCR5) antagonist, demonstrates good safety and pharmacokinetic profiles. Moyle GJ, Palleja S, Driz R, Wang-Smith L, Ogden R, Martin D, Sapirstein J HIV MED 2009 10 Suppl 2 Abs LBPE7.2/9
37. 1092299 Pharmacokinetics (PK), safety and tolerability of single doses of the chemokine C-C receptor 5 (CCR5) antagonist TBR-652 in healthy volunteers. Palleja S, Driz R, Wang-Smith L, Ogden R, Bobbitt A, Sapirstein J INT AIDS SOC CONF HIV PATHOGENESIS TREAT 2009 5 Abs WEPEB251
38. 1092303 Effect of food on the bioavailability and pharmacokinetics (PK) of TBR-652, a potent new chemokine C-C receptor 5 (CCR5) antagonist. Palleja S, Driz R, Wang-Smith L, Ogden R, Bobbitt A, Sapirstein J INT AIDS SOC CONF HIV PATHOGENESIS TREAT 2009 5 Abs WEPEB252
39. 1102912 Orally active CCR5 antagonists as anti-HIV-1 agents. Part 3: Synthesis and biological activities of 1-benzazepine derivatives containing a sulfoxide moiety. Seto M, Miyamoto N, Aikawa K, Aramaki Y, Kanzaki N, Iizawa Y, Baba M, Shirashi M BIOORG MED CHEM 2005 13 2 363-386
40. 1102913 The many roles of chemokines and chemokine receptors in inflammation. Charo IF, Ransohoff RM N ENGL J MED 2006 354 6 610-621
41. 1102916 The influence of CCL3L1 gene-containing segmental duplications on HIV-1/AIDS susceptibility. Gonzalez E, Kulkarni H, Bolivar H, Mangano A, Sanchez R, Catano G, Nibbs RJ, Freedman BI, Quinones MP, Bamshad MJ, Murthy KK et al SCIENCE, 2005, 307, 5714, 1434-1440
42. 1102917 Phase 3 trials of vicriviroc in treatment-experienced subjects demonstrate safety but not significantly superior efficacy over potent background regimens alone. Gathe J, Diaz R, Fatkenheuer G, Zeinecker J, Mak C, Vilchez R, Greaves W, Kumar S, Onyebuchi C, Dunkle L INT CONF RETROVIRUSES OPPORTUNISTIC INFECT 2010 17 Abs 54LB
43. 1102918 Potent antiretroviral activity of the once-daily CCR5 antagonist INCB009471 over 14 days of monotherapy. Cohen C, DeJesus E, Mills A, Pierone G, Kumar P, Ruane P, Elion R, Fusco G, Levy R, Solomon K, Erickson-Viitanen S INT AIDS SOC CONF HIV PATHOGENESIS TREAT, 2007 4 Abs TUAB106
44. 1106003 HIV entry inhibitors: Mechanisms of action and resistance pathways. Briz V, Poveda E, Soriano V J ANTIMICROB CHEMOTHER 2006 57 4 619-627
45. 1106004 Prevalence of transmitted antiretroviral drug resistance among newly-diagnosed HIV-1-infected persons, US, 2007. Kim D, Wheeler W, Ziebell R, Johnson J, Prejaean J, Heneine W, Hall I INT CONF RETROVIRUSES OPPORTUNISTIC INFECT 2010 Abs 580
46. 1106006 Methods for estimating the prevalence of multidrug resistance in ART-experienced patients in North America. Abraham A, Gange S, Moore R, Lau B, Harrigan R, Deeks S INT CONF RETROVIRUSES OPPORTUNISTIC INFECT 2010 Abs 584
47. 1107223 Genetic deficiency of chemokine receptor CCR5 is a strong risk factor for symptomatic West Nile virus infection: A meta-analysis of 4 cohorts in the US epidemic. Lim JK, Louie CY, Glaser C, Jean C, Johnson B, McDermott DH, Murphy PM J INFECT DIS 2008 197 2 262-265
48. 1107228 Chemokine receptor CCR5 promotes leukocyte trafficking to the brain and survival in West Nile virus infection. Glass WG, Lim JK, Cholera R, Pletnev AG, Gao JL, Murphy PM J EXP MED 2005 202 8 1087-1098
49. 1107232 A chemokine receptor CCR2 allele delays HIV-1 disease progression and is associated with a CCR5 promoter mutation. Kostrikis LG, Huang Y, Moore JP, Wolinsky SM, Zhang L, Guo Y, Deutsch L, Phair J, Neumann AU, Ho DD NAT MED 1998 4 3 350-353
50. 1107233 Role of CCR2 genotype in the clinical course of syncytium-inducing (SI) or non-SI human immunodeficiency virus type 1 infection and in the time to conversion to SI virus variants. Van Rij RP, de Roda Husman AM, Brouwer M, Goudsmit J, Coutinho RA, Schuitemaker H J INFECT DIS 1998 178 6 1806-1811
51. 1107235 Accelerated immunodeficiency by anti-CCR5 treatment in HIV infection. Weinberger AD, Perelson AS, Riberiro RM, Weinberger LS PLOS COMPUTATIONAL BIOLOGY 2009 5 8 1-9
52. 1107236 The CCL7-CCL2-CCR2 axis regulates IL-4 production in lungs and fungal immunity. Szymczak W, Deepe Jr GS J IMMUNOL 2009 183 3 1964-1974